

July 14, 2023

Ono Pharmaceutical Co., Ltd.

Notice concerning Completion of Disposal of Treasury Shares as Tenure-based Restricted Stock Remuneration and Performance-linked Restricted Stock Remuneration

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO, Gyo Sagara; the “Company”) announced that the payment procedures were completed on July 14, 2023 as follows for disposal of treasury shares as tenure-based restricted stock remuneration and performance-linked restricted stock remuneration resolved at the Board of Directors meeting held on June 22, 2023. For more details, please refer to “Announcement on Disposal of Treasury Shares as Tenure-based Restricted Stock-based Remuneration and Performance-linked Restricted Stock-based Remuneration” dated June 22, 2023.

Overview of Disposal of Treasury Shares

1. Disposal as tenure-based restricted stock remuneration

(1) Disposal date	July 14, 2023
(2) Class and number of disposed shares	15,300 shares of common stock of the Company
(3) Disposal price	¥2,767 per share
(4) Total value of disposed share	¥42,335,100
(5) Allottees and number thereof; number of disposed shares	Board of Directors of the Company (excluding Outside Directors): 4 persons / 15,300 shares

2. Disposal as performance-linked restricted stock remuneration

(1) Disposal date	July 14, 2023
(2) Class and number of disposed shares	30,900 shares of common stock of the Company
(3) Disposal price	¥2,767 per share
(4) Total value of disposed share	¥85,500,300
(5) Allottees and number thereof; number of disposed shares	Board of Directors of the Company (excluding Outside Directors): 4 persons / 20,100 shares Corporate Officers who are not the Board of Directors of the Company: 7 persons / 10,800 shares

Contact:

Ono Pharmaceutical Co., Ltd.

Corporate Communications

public_relations@ono-pharma.com